The U.S.
Food and Drug Administration (FDA) on Monday named seven companies selected for its FDA PreCheck Pilot Program.
The initiative aims at strengthening domestic pharmaceutical manufacturing, improving the resilience of the U.S. drug supply chain and providing companies with earlier regulatory engagement as they build new U.S. production facilities.
Read Also: White House Denies Report Linking Trump To Eli Lilly's Experimental Obesity Treatment: 'Not For The President' Seven Companies Selected The selected participants include Amneal Pharmaceuticals Inc.
(NASDAQ:AMRX), Cellares Corp., Eli Lilly and Co.
